Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 9DX: Adjuvant Nivolumab in Hepatocellular Carcinoma
NCT03383458Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2018
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Apr 2018; status: active, not recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03383458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383458.